IL2 and neoplasm: Although this tumour is highly resistant to chemotherapy and hormone therapy, promising results have been reported with the use of molecular agents that is, recombinant cytokines, notably recombinant interleukin-2 (IL-2) and interferon-α (IFN-α), given intravenously, subcutanously alone or in combination in outpatient regimens with objective response rates between 6 and 31% (Rosenberg et al, 1987; Atzpodien et al, 1990; Sleijfer et al, 1992; Jayson et al, 1998; Tourani et al, 2003).